MarketPR
MACROABM Industries beats non-GAAP EPS estimate, raises full-year guidanceSep 8MARKETSNovartis shares fall more than 10% as del-desiran trial marks third setback in a weekSep 8DEALSFNWD declares $0.12 quarterly cash dividend, payment set for September 25Sep 8METAAckman and Tepper raised Meta Platforms stakes in Q2, with costs now the central question for the tapeSep 8MACROWhite-hat actors pull 4,000 Bitcoin from Liquid Network's federation reservesSep 7$BTCBitcoin fund flows signal rate bet, not exit: CoinSharesSep 7REGULATORYArion Carter turns $427 NCAA suspension into tackle-by-tackle cancer fundraiser for Nashville womenSep 7NVDADell Technologies AI server backlog reaches $95 billion, with fiscal second-quarter revenue at a record $47 billionSep 7$BTCBitwise sees Bitcoin above $100,000 before year-end, cites $1.3 million target for 2035Sep 7JPMJPMorgan and Morgan Stanley face shareholder suits over buyout advisory rolesSep 7MACROABM Industries beats non-GAAP EPS estimate, raises full-year guidanceSep 8MARKETSNovartis shares fall more than 10% as del-desiran trial marks third setback in a weekSep 8DEALSFNWD declares $0.12 quarterly cash dividend, payment set for September 25Sep 8METAAckman and Tepper raised Meta Platforms stakes in Q2, with costs now the central question for the tapeSep 8MACROWhite-hat actors pull 4,000 Bitcoin from Liquid Network's federation reservesSep 7$BTCBitcoin fund flows signal rate bet, not exit: CoinSharesSep 7REGULATORYArion Carter turns $427 NCAA suspension into tackle-by-tackle cancer fundraiser for Nashville womenSep 7NVDADell Technologies AI server backlog reaches $95 billion, with fiscal second-quarter revenue at a record $47 billionSep 7$BTCBitwise sees Bitcoin above $100,000 before year-end, cites $1.3 million target for 2035Sep 7JPMJPMorgan and Morgan Stanley face shareholder suits over buyout advisory rolesSep 7
NewsMacro

Novartis shares fall more than 10% as del-desiran trial marks third setback in a week

Del-desiran trial results disappointed investors on Tuesday, sending Novartis (NVS) shares down more than 10% and marking the company's third clinical setback in a single week. Three misses compressed into that window carry their own signal beyond any individual dataset.

By Miles BroadbentMacro DeskSeptember 8, 20262 min read
Share

Key takeaways

  • Novartis shares fell more than 10% on Tuesday after disappointing del-desiran trial results.
  • The del-desiran miss was Novartis's third clinical setback within a single week.
  • The market's concern has shifted from individual project risk to the strength and timing of Novartis's broader pipeline.
  • The session's decline reflected both the specific del-desiran readout and the compounding effect of three consecutive disappointments.
  • Investors are watching for any forthcoming Novartis clinical readout and whether management addresses the string of results.

Del-desiran trial results disappointed investors on Tuesday, sending Novartis (NVS) shares down more than 10% and marking the company's third clinical setback in a single week. Three misses compressed into that window carry their own signal beyond any individual dataset.

One trial failure registers as project-level risk. Three in quick succession shifts the market's attention to a broader question: what the pipeline can offer as a counterweight, and how soon. Del-desiran is the latest entry in that sequence, and the tape has now had three consecutive data points to price.

The session's decline reflects both the specific del-desiran read and the compounding effect of the pattern surrounding it. The setup for NVS from here depends on how the market assigns probability to remaining pipeline catalysts after a week that produced three straight disappointments with nothing on the other side of the ledger.

What to watch: any forthcoming clinical readout from Novartis, and whether management directly addresses the current string of results.

About this story

Filed by the macro desk of MarketPR on September 8, 2026. Source: cnbc.com. Indicative figures are not investment advice.

←Back to the news index

More from the Newsroom

All stories →
01Macro

Shein's shaky Hong Kong debut puts the reacceleration question in play

Shein's Hong Kong stock market entry has landed with "shaky" as its early descriptor, and the fast-fashion retailer's IPO is in focus for the question that matters more to the setup than opening-session reception: whether the company can…

Miles Broadbent2 min read
02Macro · NVDA

Nvidia agrees to acquire Hugging Face in $11.9 billion deal, with close targeted for first half of 2027

In focus for NVDA: Nvidia has agreed to acquire Hugging Face in a transaction valued at approximately $11.9 billion for shareholders, with the close expected in the first half of 2027, pending regulatory approval

Grant Halloran2 min read
03Macro

Shipping stocks at a crossroads as Strait of Hormuz crisis drives decade-best rally

Shipping stocks are in focus. A months-long crisis in the Strait of Hormuz has turned an overlooked corner of the market into one of 2026's hottest trades, and the sector is now at a crossroads in the midst of its

Grant Halloran2 min read

Frequently asked

Why did Novartis shares fall more than 10%?

Shares dropped after disappointing del-desiran trial results, which marked the company's third clinical setback in a single week.

What makes three setbacks in a week significant?

A single failure reads as project-level risk, but three in quick succession shifts market attention to what the broader pipeline can offer as a counterweight and how soon.

What is del-desiran in this context?

Del-desiran is the latest of three consecutive Novartis trial results, and its disappointing readout was the third data point the market had to price in that week.

What should investors watch going forward?

Investors should watch for any forthcoming clinical readout from Novartis and whether management directly addresses the current string of results.